Previous work has shown that OPTN is a negative regulator of NF-κB and IRF3 signalling, and that ALS mutations or loss of ubiquitin binding perturb these functions (Mankouri et al., 2010; Nakazawa et al., 2016). Here, OPTN is linked to amyotrophic lateral sclerosis.